CA-125 monitored therapy with GnRH analogue of pelvic endometriosis

Acta Eur Fertil. 1992 Jul-Aug;23(4):171-4.

Abstract

Thirteen patients affected by endometriosis have been treated with GnRH analogue Buserelin. CA-125 serum levels have been monitored before, during and after treatment. Analysis of data suggests the hypothesis of an individualized follow up by means of repeated assays of CA-125 and their reference to pre and post treatment graphs.

MeSH terms

  • Adult
  • Analysis of Variance
  • Antigens, Tumor-Associated, Carbohydrate / blood*
  • Buserelin / adverse effects
  • Buserelin / therapeutic use*
  • Endometriosis / blood
  • Endometriosis / diagnosis*
  • Endometriosis / drug therapy
  • Estradiol / blood
  • Female
  • Follicle Stimulating Hormone / blood
  • Follow-Up Studies
  • Humans
  • Luteinizing Hormone / blood
  • Menstrual Cycle / metabolism
  • Pelvic Neoplasms / diagnosis*
  • Pelvic Neoplasms / drug therapy
  • Pelvic Neoplasms / immunology
  • Progesterone / blood

Substances

  • Antigens, Tumor-Associated, Carbohydrate
  • Progesterone
  • Estradiol
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Buserelin